PDF herunterladen
Pharmacopsychiatry 2009; 42(3): 114-121
DOI: 10.1055/s-0028-1112134
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Switching to Aripiprazole in Outpatients with Schizophrenia Experiencing Insufficient Efficacy and/or Safety/Tolerability Issues with Risperidone: A Randomized, Multicentre, Open-label Study

V. Ryckmans 1 , J. P. Kahn 2 , S. Modell 3 , C. Werner 4 , R. D. McQuade 5 , W. Kerselaers 6 , J. Lissens 6 , R. Sanchez 5
  • 1Cabinet de Consultations, Avenue Vanhaelen, Brussels, Belgium
  • 2CHU de Nancy, Service Psychiatrie et Psychologie Clinique, Nancy, France
  • 3Bristol-Myers Squibb, Munich, Germany
  • 4Otsuka Pharma GmbH, Frankfurt, Germany
  • 5Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA
  • 6Bristol-Myers Squibb, Braine l’Alleud, Belgium
Weitere Informationen

Publikationsverlauf

received 17.07.2008 revised 07.11.2008

accepted 14.11.2008

Publikationsdatum:
18. Mai 2009 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Introduction: This study evaluated the safety/tolerability and effectiveness of aripiprazole titrated-dose versus fixed-dose switching strategies from risperidone in patients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues.

Methods: Patients were randomized to an aripiprazole titrated-dose (starting dose 5 mg/day) or fixed-dose (dose 15 mg/day) switching strategy with risperidone down-tapering. Primary endpoint was rate of discontinuation due to adverse events (AEs) during the 12-week study. Secondary endpoints included positive and negative syndrome scale (PANSS), clinical global impressions – improvement of illness scale (CGI-I), preference of medication (POM), subjective well-being under neuroleptics (SWN-K) and GEOPTE (Grupo Español para la Optimización del Tratamiento de la Esquizofrenia) scales.

Results: Rates of discontinuations due to AEs were similar between titrated-dose and fixed-dose strategies (3.5% vs. 5.0%; p=0.448). Improvements in mean PANSS total scores were similar between aripiprazole titrated-dose and fixed-dose strategies (−14.8 vs. −17.2; LOCF), as were mean CGI-I scores (2.9 vs. 2.8; p=0.425; LOCF) and SWN-K scores (+8.6 vs.+10.3; OC,+7.8 vs.+9.8; LOCF).

Conclusion: Switching can be effectively and safely achieved through a titrated-dose or fixed-dose switching strategy for aripiprazole, with down-titration of risperidone.

Key words

schizophrenia - discontinuation - dosing - switching strategies - atypical antipsychotics - effectiveness

References

  • 1 Aguglia E, De Vanna M, Onor ML. et al . Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.  Prog Neuropsychopharmacol Biol Psychiatry. 2002;  26 1229-1233
    CrossrefPubMedSuche in Google Scholar
  • 2 Alvarez E, Bobes J, Gomez JC. et al . Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia.  A naturalistic study. Eur Neuropsychopharmacol. 2003;  13 39-48
    PubMedSuche in Google Scholar
  • 3 Barkic J, Filakovic P, Radanovic-Grguric L. et al . The influence of risperidone on cognitive functions in schizophrenia.  Coll Antropol. 2003;  27 ((Suppl 1)) 111-118
    PubMedSuche in Google Scholar
  • 4 Casey DE, Carson WH, Saha AR. et al . Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.  Psychopharmacology (Berl). 2003;  166 391-399
    PubMedSuche in Google Scholar
  • 5 Chouinard G, Jones BD, Annable L. Neuroleptic-induced supersensitivity psychosis.  Am J Psychiatry. 1978;  135 1409-1410
    PubMedSuche in Google Scholar
  • 6 Correll CU. Real-life switching strategies with second-generation antipsychotics.  J Clin Psychiatry. 2006;  67 160-161
    PubMedSuche in Google Scholar
  • 7 Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N. et al . Switching between second-generation antipsychotics: why and how?.  CNS Drugs. 2005;  19 27-42
    CrossrefPubMedSuche in Google Scholar
  • 8 Fleischhacker WW, Hummer M. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes.  Drugs. 1997;  53 915-929
    PubMedSuche in Google Scholar
  • 9 Garcia-Cabeza I, Gomez JC, Sacristan JA. et al . Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).  BMC Psychiatry. 2001;  1 7
    CrossrefPubMedSuche in Google Scholar
  • 10 Guy W. Clinical Global Impressions (CGI). In: ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health 1976: 218-222
    Suche in Google Scholar
  • 11 Harvey PD, Siu CO, Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.  Psychopharmacology (Berl). 2004;  172 324-332
    CrossrefPubMedSuche in Google Scholar
  • 12 Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures.  Psychol Med. 1992;  22 347-352
    PubMedSuche in Google Scholar
  • 13 Kapur S, Zipursky R, Jones C. et al . Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.  Am J Psychiatry. 2000;  157 514-520
    CrossrefPubMedSuche in Google Scholar
  • 14 Kay SR, Fiszbein A, Opler LA. Positive and Negative Syndrome Manual. North Tonawanda, NY:Multi-Health Systems 1987
  • 15 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia.  Schizophr Bull. 1987;  13 261-276
    CrossrefPubMedSuche in Google Scholar
  • 16 Kinon BJ, Basson BR, Gilmore JA. et al . Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.  J Clin Psychiatry. 2000;  61 833-840
    PubMedSuche in Google Scholar
  • 17 Kolotkin RL, Crosby RD, Corey-Lisle PK. et al . Performance of a weight-related measure of Quality of Life in a psychiatric sample.  Qual Life Res. 2006;  15 587-596
    CrossrefPubMedSuche in Google Scholar
  • 18 Kolotkin RL, Crosby RD, Kosloski KD. et al . Development of a brief measure to assess quality of life in obesity.  Obes Res. 2001;  9 102-111
    CrossrefPubMedSuche in Google Scholar
  • 19 Loebel A, Siu C, Romano S. Improvement in prosocial functioning after a switch to ziprasidone treatment.  CNS Spectr. 2004;  9 357-3644
    PubMedSuche in Google Scholar
  • 20 Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs.  Am J Psychiatry. 1980;  137 1395-1398
    PubMedSuche in Google Scholar
  • 21 Masand PS. A review of pharmacologic strategies for switching to atypical antipsychotics.  Prim Care Companion J Clin Psychiatry. 2005;  7 121-129
    PubMedSuche in Google Scholar
  • 22 Masand PS, Berry SL. Switching antipsychotic therapies.  Ann Pharmacother. 2000;  34 200-207
    PubMedSuche in Google Scholar
  • 23 McEvoy JP, Lieberman JA, Stroup TS. et al . Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.  Am J Psychiatry. 2006;  163 600-610
    Suche in Google Scholar
  • 24 MacGahuey CA, Gelenberg AJ, Laukes CA. et al . The Arizona Sexual Experience Scale (ASEX): reliability and validity.  J Sex Marital Ther. 2000;  26 25-40
    PubMedSuche in Google Scholar
  • 25 Naber D, Moritz S, Lambert M. et al . Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs.  Schizophr Res. 2001;  50 79-88
    CrossrefPubMedSuche in Google Scholar
  • 26 Peuskens J. Switching approach in the management of schizophrenia patients.  Int Clin Psychopharmacol. 2000;  15 ((Suppl 4)) S15-19
    PubMedSuche in Google Scholar
  • 27 Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others?.  Psychopharmacology (Berl). 2000;  148 3-15
    PubMedSuche in Google Scholar
  • 28 Sanjuan J, Prieto L, Olivares JM. et al . GEOPTE Scale of social cognition for psychosis.  Actas Esp Psiquiatr. 2003;  31 120-128
    PubMedSuche in Google Scholar
  • 29 Stip E. Novel antipsychotics: issues and controversies.  Typicality of atypical antipsychotics. J Psychiatry Neurosci. 2000;  25 137-153
    PubMedSuche in Google Scholar
  • 30 Stroup TS, Lieberman JA, MacEvoy JP. et al . Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.  Am J Psychiatry. 2006;  163 611-622
    CrossrefPubMedSuche in Google Scholar
  • 31 Tandon R, Devellis RF, Han J. et al . Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder.  Psychiatry Res. 2005;  136 211-221
    CrossrefPubMedSuche in Google Scholar
  • 32 Tandon R, Marcus RN, Stock EG. et al . A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).  Schizophr Res. 2006;  84 77-89
    CrossrefPubMedSuche in Google Scholar
  • 33 Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.  J Clin Psychiatry. 2007;  68 ((Suppl 1)) 12-19
    PubMedSuche in Google Scholar
  • 34 Weiden PJ, Aquila R, Dalheim L. et al . Switching antipsychotic medications.  J Clin Psychiatry. 1997;  58 ((Suppl 10)) 63-72
    PubMedSuche in Google Scholar
  • 35 Weiden PJ, Simpson GM, Potkin SG. et al . Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.  J Clin Psychiatry. 2003;  64 580-588
    CrossrefPubMedSuche in Google Scholar
  • 36 Wolf J, Janssen F, Lublin H. et al . A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA).  Curr Med Res Opin. 2007;  23 2313-2323
    CrossrefPubMedSuche in Google Scholar

1 History: Poster presented at: Annual General Meeting of the Swedish Society of Medicine, Stockholm, Sweden, 28–10 November 2007; West European Societies of Biological Psychiatry (WEBP), Strasbourg, France, 13-15 December 2007.

Correspondence

Prof. V. Ryckmans

Cabinet de Consultations

Avenue Vanhaelen 25

1160 Brussels

Belgium

Telefon: +32/26/729 422

Fax: +32/26/729 422

eMail: vincent.ryckmans@yahoo.fr